SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 9, 2020
OptimizeRx Corporation
(Exact name of registrant as specified in its charter)
| Nevada | 001-38543 | 26-1265381 | ||
| (State
or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S.
Employer Identification No.) |
| 400 Water Street, Suite 200, Rochester, MI | 48307 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: 248.651.6568
|
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name of each exchange on which registered | ||
| Common Stock | OPRX | Nasdaq Capital Market |
SECTION 8 – Other Events
| Item 8.01 | Other Events |
On June 9, 2020, we issued a press release announcing that we have finalized a new partnership that expands our digital communication platform by more than 300 health systems and 75,000 healthcare providers that utilize market-leading EHRs Epic and Cerner. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SECTION 9 – Financial Statements and Exhibits
| Item 9.01 | Financial Statements and Exhibits |
| 99.1 | Press release, dated June 9, 2020 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OptimizeRx Corporation | |
| /s/ Douglas Baker | |
| Douglas Baker | |
| Chief Financial Officer | |
| Date June 10, 2020 |
2
Exhibit 99.1
OptimizeRx Digital Health Platform Adds More than 300 Epic and Cerner Health Systems
ROCHESTER, Mich. – June 9, 2020 – OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, payers, providers, and patients, has finalized a new partnership that expands its digital communication platform by more than 300 health systems and 75,000 healthcare providers that utilize market-leading EHRs Epic and Cerner.
Healthcare providers within these health systems will now have instant access to real-time patient savings information via OptimizeRx’s cloud-based platform as they are evaluating and prescribing treatments.
Linked to as much as $528 billion in avoidable healthcare costs annually, medication non-adherence is a focal point of healthcare industry performance improvement efforts.
High out-of-pocket prescription drug costs drives non-adherence even in good economic times. With 33% of Americans delaying treatment due to cost in 2019, this percentage is likely to rise given the current COVID-19 related economic challenges. Increased price transparency within the provider daily workflow is one area of improvement that can make a difference in treatment adherence.
“Especially in these challenging times, patients need help with the cost of healthcare,” commented Miriam Paramore, president of OptimizeRx. “Often patients cannot afford their medications and therefore never get them. We are focused on expanding our network to every EHR, so that every provider and every patient can easily access the prescription savings that are available on every drug. This expansion of our network reach is a huge step that will connect us to an additional 120 million patients, given the market dominance of Epic and Cerner.”
The OptimizeRx platform now reaches more than 675,000 prescribers directly within their existing digital workflows, simplifying communication and improving transparency. The expansion represents an 11% growth for the nation’s largest point-of-prescribe network, which has traditionally been focused on the ambulatory care setting.
“As we start to approach 2021 planning with our clients, the increased need for access to point-of-care communication with affordability tools for physicians and patients has never been so critical,” said Will Febbo, CEO of OptimizeRx. “This further expansion into Epic and Cerner systems builds on previous integrations and gives us additional scale in the inpatient care setting. From within provider workflow, we are able to provide information to support the necessary financial discussions between physicians and patients when selecting treatment.”
For more information on OptimizeRx, its products or other news, visit www.optimizerx.com.
About OptimizeRx
OptimizeRx Corporation (NASDAQ: OPRX) is a digital health company that facilitates communication at point-of-care among all stakeholders in healthcare. Primarily focused on life science and payer clients, its suite of digital and mobile SaaS-based solutions enables affordability, patient adherence and care management. OptimizeRx’s network reaches more than 60% of U.S. ambulatory providers, delivering therapeutic support on specialty medications and patient financial assistance directly within a provider’s workflow through leading electronic health platforms. OptimizeRx’s fully integrated platform supports the real-time exchange of information, improving provider knowledge and patient engagement, and ultimately leading to healthier outcomes.
For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words ‘estimate,’ ‘possible’ and ‘seeking’ and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
OptimizeRx Contact
Doug Baker, CFO
Tel (248) 651-6568 (x807)
dbaker@optimizerx.com
Media Relations Contact
Maira Alejandra, Media Relations Manager
Tel (754) 245-7070
malejandra@optimizerx.com
Investor Relations Contact
Ron Both, CMA
Tel (949) 432-7557
oprx@cma.team